Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. [electronic resource]
Producer: 20021217Description: 875-83 p. digitalISSN:- 1539-3704
- Adult
- Aged
- Aged, 80 and over
- Alendronate -- adverse effects
- Biomarkers -- analysis
- Bone Density -- drug effects
- Double-Blind Method
- Drug Therapy, Combination
- Estrogen Replacement Therapy -- adverse effects
- Estrogens, Conjugated (USP) -- adverse effects
- Female
- Hip -- physiology
- Humans
- Lumbar Vertebrae -- drug effects
- Middle Aged
- Osteoporosis, Postmenopausal -- drug therapy
- Placebos
- Treatment Outcome
- Withholding Treatment
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.